← Back to Search

Anti-metabolites

5-Fluorouracil + Calcipotriene Cream for Skin Cancer

Phase 2 & 3
Recruiting
Led By Bilal Fawaz, MD
Research Sponsored by Boston University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Having a previously untreated, biopsy-proven sBCC or SCCis on the face, hands, feet, and genitalia who decline surgery or are otherwise not surgical candidates
Having a previously untreated, biopsy-proven Superficial Basal Cell Carcinoma (sBCC) or Squamous Cell Carcinoma in Situ (SCCis) of the skin <2 cm on the scalp, trunk, neck, or extremities, excluding hands, feet, and genitalia
Must not have
Periorbital lesions
Genetic disorders associated with high skin cancer risk
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 years
Awards & highlights

Summary

This trial compares a standard cancer-killing cream with a new, potentially more effective cream. It targets patients with less aggressive skin cancers. The new cream might work better by combining two ingredients to kill cancer cells and prevent new ones from forming.

Who is the study for?
This trial is for English-speaking adults with low-risk skin cancers (sBCC or SCCis) on certain body parts, who haven't had treatment yet and aren't good candidates for surgery. They must be willing to follow the study plan and attend follow-ups. Women of childbearing age need a negative pregnancy test before starting and must use birth control during the study.
What is being tested?
The trial compares two creams: one with just 5-fluorouracil, an FDA-approved treatment, against a mix of 5-fluorouracil and calcipotriene. The goal is to see if the combo cream can clear cancer in a shorter time (7-14 days). Participants will be checked over three years to see if their skin cancer has been treated successfully.
What are the potential side effects?
Possible side effects include skin irritation, redness, burning sensation where the cream is applied, increased sensitivity to sunlight leading to sunburns more easily than usual, changes in skin color at the application site, itching or rash.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have a skin cancer diagnosis on sensitive areas and cannot or do not wish to undergo surgery.
Select...
I have a skin cancer diagnosis that hasn't been treated and is smaller than 2 cm, not on my hands, feet, or private areas.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have lesions around my eye area.
Select...
I have a genetic condition that increases my risk for skin cancer.
Select...
I have been diagnosed with cutaneous T-cell lymphoma.
Select...
I have had treatments on my lesions before.
Select...
I am not pregnant or breastfeeding.
Select...
I have a deficiency in the DPD enzyme.
Select...
My condition affects the mouth, nose, or genital areas.
Select...
I have been exposed to arsenic.
Select...
I have had an organ transplant or am currently on immunosuppressants.
Select...
I have had radiation therapy on the skin cancer area.
Select...
I have had PUVA therapy at the affected site.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Clearance rate of cancer lesions at 3 months
Clearance rate of cancer lesions at 3 years
Secondary study objectives
Day of worst redness
Participant compliance with treatment
Participant satisfaction with treatment
+9 more

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Combination cream of 5-fluorouracil and calcipotrieneExperimental Treatment1 Intervention
Participants randomized to this group will receive treatment with the combination cream consisting of 5-fluorouracil and calcipotriene twice a day for 7 days and the treatment can be extended to 14 days based on evaluation at 7 days.
Group II: 5-fluorouracil creamActive Control1 Intervention
Participants randomized to this group will receive treatment with 5-fluorouracil cream twice a day for 28 days.

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
5-Fluorouracil (5-FU) works by inhibiting DNA synthesis in cancer cells, leading to cell death, which is particularly effective in rapidly dividing cells like those in Basal Cell Carcinoma (BCC). Calcipotriene, a synthetic vitamin D derivative, modulates cell differentiation and proliferation, normalizing skin cell growth and enhancing the effectiveness of 5-FU. These mechanisms are crucial for BCC patients as they target cancerous cells specifically, aiming to minimize damage to healthy tissue.
Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy.

Find a Location

Who is running the clinical trial?

Boston UniversityLead Sponsor
470 Previous Clinical Trials
9,962,880 Total Patients Enrolled
Bilal Fawaz, MDPrincipal InvestigatorDermatology, Boston University School of Medicine

Media Library

5-Fluorouracil (Anti-metabolites) Clinical Trial Eligibility Overview. Trial Name: NCT05381597 — Phase 2 & 3
Basal Cell Carcinoma Research Study Groups: Combination cream of 5-fluorouracil and calcipotriene, 5-fluorouracil cream
Basal Cell Carcinoma Clinical Trial 2023: 5-Fluorouracil Highlights & Side Effects. Trial Name: NCT05381597 — Phase 2 & 3
5-Fluorouracil (Anti-metabolites) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05381597 — Phase 2 & 3
~45 spots leftby Jun 2025